Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Remi Adelaiye, Eric Ciamporcero, Kiersten Marie Miles, Paula Sotomayor, Jonathan Bard, Maria Tsompana, Dylan Conroy, Li Shen, Swathi Ramakrishnan, Sheng Yu Ku, Ashley Orillion, Joshua Prey, Gerald Fetterly, Michael Buck, Sreenivasulu Chintala, Georg A. Bjarnasone, Roberto Pili

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance may be transient and could be overcome by dose increase. In selected patients initially treated with 50 mg sunitinib and presenting with minimal toxicities, sunitinib dose was escalated to 62.5 mg and/or 75 mg at the time of tumor progression. Mice bearing two different patient-derived ccRCC xenografts (PDX) were treated 5 days per week with a dose-escalation schema (40-60-80 mg/kg sunitinib). Tumor tissues were collected before dose increments for immunohistochemistry analyses and drug levels. Selected intrapatient sunitinib dose escalation was safe and several patients had added progression-free survival. In parallel, our preclinical results showed that PDXs, although initially responsive to sunitinib at 40 mg/kg, eventually developed resistance. When the dose was incrementally increased, again we observed tumor response to sunitinib. A resistant phenotype was associated with transient increase of tumor vasculature despite intratumor sunitinib accumulation at higher dose. In addition, we observed associated changes in the expression of the methyltransferase EZH2 and histone marks at the time of resistance. Furthermore, specific EZH2 inhibition resulted in increased in vitro antitumor effect of sunitinib. Overall, our results suggest that initial sunitinib-induced resistance may be overcome, in part, by increasing the dose, and highlight the potential role of epigenetic changes associated with sunitinib resistance that can represent new targets for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)513-522
Number of pages10
JournalMolecular Cancer Therapeutics
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Epigenomics
sunitinib
Neoplasms
Histone Code
Methyltransferases
Drug Resistance
Heterografts
Disease-Free Survival
Disease Progression
Immunohistochemistry
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. / Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie; Sotomayor, Paula; Bard, Jonathan; Tsompana, Maria; Conroy, Dylan; Shen, Li; Ramakrishnan, Swathi; Ku, Sheng Yu; Orillion, Ashley; Prey, Joshua; Fetterly, Gerald; Buck, Michael; Chintala, Sreenivasulu; Bjarnasone, Georg A.; Pili, Roberto.

In: Molecular Cancer Therapeutics, Vol. 14, No. 2, 01.02.2015, p. 513-522.

Research output: Contribution to journalArticle

Adelaiye, R, Ciamporcero, E, Miles, KM, Sotomayor, P, Bard, J, Tsompana, M, Conroy, D, Shen, L, Ramakrishnan, S, Ku, SY, Orillion, A, Prey, J, Fetterly, G, Buck, M, Chintala, S, Bjarnasone, GA & Pili, R 2015, 'Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications', Molecular Cancer Therapeutics, vol. 14, no. 2, pp. 513-522. https://doi.org/10.1158/1535-7163.MCT-14-0208
Adelaiye, Remi ; Ciamporcero, Eric ; Miles, Kiersten Marie ; Sotomayor, Paula ; Bard, Jonathan ; Tsompana, Maria ; Conroy, Dylan ; Shen, Li ; Ramakrishnan, Swathi ; Ku, Sheng Yu ; Orillion, Ashley ; Prey, Joshua ; Fetterly, Gerald ; Buck, Michael ; Chintala, Sreenivasulu ; Bjarnasone, Georg A. ; Pili, Roberto. / Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 2. pp. 513-522.
@article{b708eca536f74667b32ae7145a28b10e,
title = "Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications",
abstract = "Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance may be transient and could be overcome by dose increase. In selected patients initially treated with 50 mg sunitinib and presenting with minimal toxicities, sunitinib dose was escalated to 62.5 mg and/or 75 mg at the time of tumor progression. Mice bearing two different patient-derived ccRCC xenografts (PDX) were treated 5 days per week with a dose-escalation schema (40-60-80 mg/kg sunitinib). Tumor tissues were collected before dose increments for immunohistochemistry analyses and drug levels. Selected intrapatient sunitinib dose escalation was safe and several patients had added progression-free survival. In parallel, our preclinical results showed that PDXs, although initially responsive to sunitinib at 40 mg/kg, eventually developed resistance. When the dose was incrementally increased, again we observed tumor response to sunitinib. A resistant phenotype was associated with transient increase of tumor vasculature despite intratumor sunitinib accumulation at higher dose. In addition, we observed associated changes in the expression of the methyltransferase EZH2 and histone marks at the time of resistance. Furthermore, specific EZH2 inhibition resulted in increased in vitro antitumor effect of sunitinib. Overall, our results suggest that initial sunitinib-induced resistance may be overcome, in part, by increasing the dose, and highlight the potential role of epigenetic changes associated with sunitinib resistance that can represent new targets for therapeutic intervention.",
author = "Remi Adelaiye and Eric Ciamporcero and Miles, {Kiersten Marie} and Paula Sotomayor and Jonathan Bard and Maria Tsompana and Dylan Conroy and Li Shen and Swathi Ramakrishnan and Ku, {Sheng Yu} and Ashley Orillion and Joshua Prey and Gerald Fetterly and Michael Buck and Sreenivasulu Chintala and Bjarnasone, {Georg A.} and Roberto Pili",
year = "2015",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0208",
language = "English (US)",
volume = "14",
pages = "513--522",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

AU - Adelaiye, Remi

AU - Ciamporcero, Eric

AU - Miles, Kiersten Marie

AU - Sotomayor, Paula

AU - Bard, Jonathan

AU - Tsompana, Maria

AU - Conroy, Dylan

AU - Shen, Li

AU - Ramakrishnan, Swathi

AU - Ku, Sheng Yu

AU - Orillion, Ashley

AU - Prey, Joshua

AU - Fetterly, Gerald

AU - Buck, Michael

AU - Chintala, Sreenivasulu

AU - Bjarnasone, Georg A.

AU - Pili, Roberto

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance may be transient and could be overcome by dose increase. In selected patients initially treated with 50 mg sunitinib and presenting with minimal toxicities, sunitinib dose was escalated to 62.5 mg and/or 75 mg at the time of tumor progression. Mice bearing two different patient-derived ccRCC xenografts (PDX) were treated 5 days per week with a dose-escalation schema (40-60-80 mg/kg sunitinib). Tumor tissues were collected before dose increments for immunohistochemistry analyses and drug levels. Selected intrapatient sunitinib dose escalation was safe and several patients had added progression-free survival. In parallel, our preclinical results showed that PDXs, although initially responsive to sunitinib at 40 mg/kg, eventually developed resistance. When the dose was incrementally increased, again we observed tumor response to sunitinib. A resistant phenotype was associated with transient increase of tumor vasculature despite intratumor sunitinib accumulation at higher dose. In addition, we observed associated changes in the expression of the methyltransferase EZH2 and histone marks at the time of resistance. Furthermore, specific EZH2 inhibition resulted in increased in vitro antitumor effect of sunitinib. Overall, our results suggest that initial sunitinib-induced resistance may be overcome, in part, by increasing the dose, and highlight the potential role of epigenetic changes associated with sunitinib resistance that can represent new targets for therapeutic intervention.

AB - Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance may be transient and could be overcome by dose increase. In selected patients initially treated with 50 mg sunitinib and presenting with minimal toxicities, sunitinib dose was escalated to 62.5 mg and/or 75 mg at the time of tumor progression. Mice bearing two different patient-derived ccRCC xenografts (PDX) were treated 5 days per week with a dose-escalation schema (40-60-80 mg/kg sunitinib). Tumor tissues were collected before dose increments for immunohistochemistry analyses and drug levels. Selected intrapatient sunitinib dose escalation was safe and several patients had added progression-free survival. In parallel, our preclinical results showed that PDXs, although initially responsive to sunitinib at 40 mg/kg, eventually developed resistance. When the dose was incrementally increased, again we observed tumor response to sunitinib. A resistant phenotype was associated with transient increase of tumor vasculature despite intratumor sunitinib accumulation at higher dose. In addition, we observed associated changes in the expression of the methyltransferase EZH2 and histone marks at the time of resistance. Furthermore, specific EZH2 inhibition resulted in increased in vitro antitumor effect of sunitinib. Overall, our results suggest that initial sunitinib-induced resistance may be overcome, in part, by increasing the dose, and highlight the potential role of epigenetic changes associated with sunitinib resistance that can represent new targets for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=84923331660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923331660&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0208

DO - 10.1158/1535-7163.MCT-14-0208

M3 - Article

C2 - 25519701

AN - SCOPUS:84923331660

VL - 14

SP - 513

EP - 522

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -